Thomas Jefferson University

Michael Mastrangelo

TitleProfessor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-955-8874
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Orloff M, Brennan M, Sato S, Shields CL, Shields JA, Lally S, Mashayekhi A, Mason J, Materin M, Mastrangelo M, Sato T. Unique geospatial accumulations of uveal melanoma. Am J Ophthalmol. 2020 Jul 15. PMID: 32681908.
      Citations:    
    2. Seedor RS, Eschelman DJ, Gonsalves CF, Adamo RD, Orloff M, Amjad A, Sharpe-Mills E, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ, Sato T. An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. Cancers (Basel). 2020 Jan 01; 12(1). PMID: 31906411.
      Citations:    
    3. Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ, Sato T. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 2017 Dec; 9(16):1323-1330. PMID: 29185395.
      Citations:    
    4. Valsecchi ME, Orloff M, Sato R, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ, Sato T. Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls. Ophthalmology. 2018 Feb; 125(2):210-217. PMID: 28935400.
      Citations:    
    5. Kageyama K, Ohara M, Saito K, Ozaki S, Terai M, Mastrangelo MJ, Fortina P, Aplin AE, Sato T. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis. J Transl Med. 2017 Jun 23; 15(1):145. PMID: 28645290.
      Citations:    
    6. Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, Eldredge-Hindy H, Daskalakis C, Feeney KJ, Mastrangelo MJ, Kim LJ, Sato T, Kendra KL, Olencki T, Liebner DA, Farrell CJ, Evans JJ, Judy KD, Andrews DW, Dicker AP, Werner-Wasik M, Shi W. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2017 Sep 01; 99(1):22-30. PMID: 28816150.
      Citations:    
    7. Berger AC, Ollila DW, Christopher A, Kairys JC, Mastrangelo MJ, Feeney K, Dabbish N, Leiby B, Frank JA, Stitzenberg KB, Meyers MO. Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma. J Am Coll Surg. 2017 Apr; 224(4):652-659. PMID: 28189663.
      Citations:    
    8. Ozaki S, Vuyyuru R, Kageyama K, Terai M, Ohara M, Cheng H, Manser T, Mastrangelo MJ, Aplin AE, Sato T. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol. 2016 Jan; 186(1):43-56. PMID: 26613897.
      Citations:    
    9. Mastrangelo MJ. The Last Chapter. Semin Oncol. 2015 Dec; 42(6):923-4. PMID: 26615137.
      Citations:    
    10. Terai M, Mu Z, Eschelman DJ, Gonsalves CF, Kageyama K, Chervoneva I, Orloff M, Weight R, Mastrangelo MJ, Cristofanilli M, Sato T. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. EBioMedicine. 2015 Nov; 2(11):1821-6. PMID: 26870807.
      Citations:    
    11. Feeney KJ, Mastrangelo MJ. Intralesional therapy for in-transit and satellite metastases in melanoma. Surg Oncol Clin N Am. 2015 Apr; 24(2):299-308. PMID: 25769713.
      Citations:    
    12. Valsecchi ME, Terai M, Eschelman DJ, Gonsalves CF, Chervoneva I, Shields JA, Shields CL, Yamamoto A, Sullivan KL, Laudadio M, Berd D, Mastrangelo MJ, Sato T. Double-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte-Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic Metastases. J Vasc Interv Radiol. 2015 Apr; 26(4):523-532.e2. PMID: 25678394.
      Citations:    
    13. Yoshida M, Selvan S, McCue PA, Deangelis T, Baserga R, Fujii A, Rui H, Mastrangelo MJ, Sato T. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res. 2014 Mar; 27(2):297-308. PMID: 24354797.
      Citations:    
    14. Johnson C, Intenzo C, Mastrangelo MJ, Feeney K, Berger AC. Altered drainage patterns in patients with melanoma and previous axillary dissection. J Dermatol. 2013 Jul; 40(7):564-6. PMID: 23594177.
      Citations:    
    15. Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T. A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 2012 Dec; 22(6):440-6. PMID: 23114504.
      Citations:    
    16. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. PMID: 22168571; PMCID: PMC3338100.
      Citations:    
    17. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011 Dec; 51(2-3):170-82. PMID: 22139852.
      Citations:    
    18. Terai M, Eto M, Young GD, Berd D, Mastrangelo MJ, Tamura Y, Harigaya K, Sato T. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother. 2012 Feb; 61(2):145-55. PMID: 21853302.
      Citations:    
    19. Berger AC, Fierro M, Kairys JC, Berd D, Sato T, Andrel J, Hyslop T, Mastrangelo MJ. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. J Surg Oncol. 2012 Jan; 105(1):15-20. PMID: 21815149.
      Citations:    
    20. Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60(7):1039-45. PMID: 21519827.
      Citations:    
    21. Berencsi K, Rani P, Zhang T, Gross L, Mastrangelo M, Meropol NJ, Herlyn D, Somasundaram R. In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2. J Transl Med. 2011 Mar 30; 9:33. PMID: 21450101; PMCID: PMC3076246.
      Citations:    
    22. Nair BC, Williams NC, Cui C, Summers D, Mastrangelo MJ, Hubosky SG, Shields CL, Shields JA, Sato T. Conjunctival melanoma: bladder and upper urinary tract metastases. J Clin Oncol. 2011 Mar 20; 29(9):e216-9. PMID: 21189399.
      Citations:    
    23. de Silva S, Mastrangelo MA, Lotta LT, Burris CA, Izsvák Z, Ivics Z, Bowers WJ. Herpes simplex virus/Sleeping Beauty vector-based embryonic gene transfer using the HSB5 mutant: loss of apparent transposition hyperactivity in vivo. Hum Gene Ther. 2010 Nov; 21(11):1603-13. PMID: 20507234; PMCID: PMC2978550.
      Citations:    
    24. Kaplan FM, Mastrangelo MJ, Aplin AE. The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors. J Invest Dermatol. 2010 Nov; 130(11):2669-71. PMID: 20574441.
      Citations:    
    25. Marks JA, Rao AS, Loren D, Witkiewicz A, Mastrangelo MJ, Berger AC. Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the Ampulla of Vater. JOP. 2010; 11(2):173-5. PMID: 20208330.
      Citations:    
    26. Chapman P, Cranmer L, Dixon WG, Hyrich KL, Patterson JR, Symmons DP, Toporcer M, Mastrangelo MJ. The role of anti-tumor necrosis factor receptor agents in cancer survivors: does the risk justify the benefit? Semin Oncol. 2010 Feb; 37(1):11-9. PMID: 20172358.
      Citations:    
    27. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, Berd D, Shields JA, Shields CL, Terai M, Sato T. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology. 2009 Jul; 252(1):290-8. PMID: 19561263.
      Citations:    
    28. Mastrangelo MJ. Impact of malignant disease on young adults. Semin Oncol. 2009 Jun; 36(3):193. PMID: 19460576.
      Citations:    
    29. Terai M, Tamura Y, Alexeev V, Ohtsuka E, Berd D, Mastrangelo MJ, Sato T. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother. 2009 Aug; 58(8):1307-17. PMID: 19142637.
      Citations:    
    30. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S, LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol. 2008 Dec; 173(6):1768-82. PMID: 18974297.
      Citations:    
    31. Sato T, Eschelman DJ, Gonsalves CF, Terai M, Chervoneva I, McCue PA, Shields JA, Shields CL, Yamamoto A, Berd D, Mastrangelo MJ, Sullivan KL. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008 Nov 20; 26(33):5436-42. PMID: 18838710.
      Citations:    
    32. Samplaski MK, Rosato EL, Witkiewicz AK, Mastrangelo MJ, Berger AC. Malignant melanoma of the gallbladder: a report of two cases and review of the literature. J Gastrointest Surg. 2008 Jun; 12(6):1123-6. PMID: 18060465.
      Citations:    
    33. Retsas S, Mastrangelo MJ. Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma. Semin Oncol. 2007 Dec; 34(6):491-7. PMID: 18083372.
      Citations:    
    34. Solti M, Berd D, Mastrangelo MJ, Sato T. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res. 2007 Aug; 17(4):225-31. PMID: 17625452.
      Citations:    
    35. Mucci T, Long W, Witkiewicz A, Mastrangelo MJ, Rosato EL, Berger AC. Metastatic melanoma causing jejunal intussusception. J Gastrointest Surg. 2007 Dec; 11(12):1755-7. PMID: 17619936.
      Citations:    
    36. Berd D, Mastrangelo MJ, Sato T. Calculation of survival of patients with stage III melanoma. J Clin Oncol. 2005 Dec 20; 23(36):9427; author reply 9428. PMID: 16361644.
      Citations:    
    37. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, Sato T. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005 Aug; 15(4):297-304. PMID: 16034309.
      Citations:    
    38. Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1; 22(3):403-15. PMID: 14691123.
      Citations:    
    39. Sato T, Terai M, Yasuda R, Watanabe R, Berd D, Mastrangelo MJ, Hasumi K. Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunol Immunother. 2004 Jan; 53(1):53-61. PMID: 13680192.
      Citations:    
    40. Birebent B, Mitchell E, Akis N, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai D, Zhang T, Herlyn DM. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine. 2003 Apr 2; 21(15):1601-12. PMID: 12639481.
      Citations:    
    41. Herlyn D, Birebent B, Akis N, Purev E, Somasundaram R, Mitchell E, Maguire H, Staib L, Mastrangelo M. Colon cancer antigen and anti-idiotype vaccines. Cancer Chemother Biol Response Modif. 2003; 21:287-98. PMID: 15338751.
      Citations:    
    42. Reddy KS, Mastrangelo M, D Johnston T, Khan T, Waid T, McKeown W, Lucas B, Ranjan D. Recipient outcome following living donor kidney transplantation using kidneys procured laparoscopically. Clin Transplant. 2003; 17 Suppl 9:44-7. PMID: 12795668.
      Citations:    
    43. Mastrangelo MJ, Lattime EC. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther. 2002 Dec; 9(12):1013-21. PMID: 12522440.
      Citations:    
    44. Manne J, Mastrangelo MJ, Sato T, Berd D. TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol. 2002 Sep 15; 169(6):3407-12. PMID: 12218163.
      Citations:    
    45. Berd D, Sato T, Mastrangelo MJ. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol Immunother. 2002 Aug; 51(6):320-6. PMID: 12111120.
      Citations:    
    Mastrangelo's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (210)
    Explore
    _
    Co-Authors (41)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _